Bristol-myers Squibb Compnay

Temple University

Aventis Pharmaceuticals Inc.

Cephalon, Inc.

Aventis Pharmaceuticals Products Inc.

George C Morton

Joseph M Salvino

Timothy F Herpin

R Michael Lawrence

Wayne Everett Childers

Richard F Labaudiniere

Helen J Mason

John E Macor

Magid A Abou-Gharbia

Edward H Ruediger

Graham S Poindexter

Guixue Yu

Rejean Ruel

Carl Thibault

Jean-Pierre J Issa

Hanghang Zhang

Michael A Poss

Gregory S Bisacchi

Jacques Y Roberge

Timur Gungor

Robert P Rehfuss

Salim Merali

Carlos A Barrero

Gerard C Rosse

Uwe D Treuner

Edward R Bacon

Thomas R Bailey

Peter W Glunz

Benjamin E Blass

Rabindranath Tripathy

Xiaojun Zhang

Derek D Dunn

Greg A Hostetler

Benoit J Vanasse

Shawn P Allwein

E Scott Priestley

Babu G Sundar

Yi Wang

Matthew M Morrissette

Liang Ma

Christopher Hulme

Alexandra Holubec

Mercy Ramanjulu

Marie-Pierre Cherrier

Wayne C Childers

Magid Abu-Gharbia

Franco Manfre

Robert J McHugh

Mario Cesar Rico

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis.

(S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis

The present invention includes novel aminothiazole compounds of formula (I), which are useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of formula (I)

Aminothiazole compounds and methods using same

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.

Compositions and methods for treatment of insulin resistance

The present invention includes novel bridged bicycloalkyl-substituted aminothiazole compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

Bridged bicycloalkyl-substituted aminothiazoles and their methods of use

Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.

Beta lactams as modulators of glutamate uptake and methods for use thereof

Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R-R, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders. 

The present invention includes novel aminothiazole compounds of formula (I) useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

This application relates to tricyclic compounds of Formula I: including all stereoisomeric forms, all mixtures of stereoisomeric forms, and salts of these compounds. This application also relates to compositions comprising compounds of Formula I, stereoisomeric forms, all mixtures of stereoisomeric forms, and salts thereof and uses therefor.

Tricyclic derivatives and their pharmaceutical use and compositions

This application relates to tricyclic compounds of Formula I: including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula I and uses therefore.

The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

[object Object]

Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, or prodrugs thereof, are useful as serine protease inhibitors, wherein X is &#x2014;OH, &#x2014;O(alkyl), &#x2014;O(aryl), &#x2014;O(arylalkyl), &#x2014;NR(aryl), or &#x2014;NR(arylalkyl); W is hydrogen or &#x2014;(CRR)&#x2014;W; Wis hydrogen or a bond with R; Z is a 5-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R, R, R, R, R, R, and Rare as defined in the specification.

Benzene acetamide compounds useful as serine protease inhibitors

A method for the solid phase synthesis of N,N-disubstituted diazacycloalkylcarboxy derivatives of general formula (I) and (II) is claimed. Examples include piperazine-2-carboxamide. The method is applicable to the synthesis or large combinatorial libraries 

Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives

Compounds having the formula (I), or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is &#x2014;NRS(O)R; W is hydrogen or &#x2014;(CRR)W; Wis hydrogen or a bond with R; Z is a-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, atomembered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R, R, R, R, R, and Rare as defined in the specification.

Phenylglycine derivatives useful as serine protease inhibitors

Compounds having the formula (I), G is a novel side chain selected from Calkenyl, A-aryl, &#x2014;OR, heteroaryl, A-cyano, A&#x2014;OR, A&#x2014;C(&#x2550;O)R, A&#x2014;COR, A&#x2014;C(&#x2550;O)NRR, A&#x2014;OC(&#x2550;O)R, A&#x2014;NRC(&#x2550;O)R, A&#x2014;OC(&#x2550;O)NRR, A&#x2014;NRCOR, A&#x2014;NRSOR, A&#x2014;SOR, A&#x2014;NRC(&#x2550;O)NRR, and A&#x2014;SR; or when y is 0 or when W is not NHR, G may be A-heterocyclo, wherein Ais a bond, Calkylene or C-alkenylene, Ais Calkylene or Calkenylene, and Ais Calkenylene; W is selected from &#x2014;NRR, &#x2014;OR, &#x2014;NRC(&#x2550;O)R, &#x2014;NRCOR, amidino, guanidino, or a heteroaryl, heterocyclo or Ccycloalkyl as defined in the specification, and X and Rthrough Rare as defined in the specification, are effective as modulators of melanocortin-receptors, particularly MC-1R and MC-4R.

Compounds useful as modulators of Melanocortin Receptors and pharmaceutical compositions comprising same

Growing community of inventors

Collegeville, PA, United States of America

George C Morton